One screen. Rugiet's five-dimension profile, the revenue triangulation that sets the valuation, the reported $31M loan we read as ranking ahead of any new check, and the verify list that closes the gap between the headline and what diligence can confirm. Every Rugiet figure carries its company-asserted qualifier; the compounded, not-FDA-approved status of the core product is verified.
One screen. Rugiet's five-dimension profile (top-left) carries the shape the whole report turns on: Product/Formulation and Regulatory Standing and Acquisition control are the two lowest, the formulation real but the channel and capital thin. The revenue triangulation (top-right) is the decision: >$100M company-asserted against a $10–25M tracker band and our $15–40M read — a gap that cannot be priced until audited financials close it. The reported $31M loan (mid-left) we read as ranking ahead of any new equity, so a follow-on would sit junior to it; the rising market (mid-right) intensifies the acquisition-cost competition Rugiet is least equipped to win, with its compounded weight-loss line walking into active FDA enforcement. The verify list along the bottom is the path: audited revenue, the loan terms, the apomorphine dose, the claim substantiation, the compounding structure. The formulation is differentiated; the business is sub-scale, unverified, and senior-debt-funded. Underwrite to the tracker range and verify before any check.